Audio-vestibular Evaluation of Children and Young Adults With Osteogenesis Imperfecta
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at children and young adults aged 12 to 20 who have a condition called Osteogenesis Imperfecta (OI), which is also known as brittle bone disease. The main goal is to find out if people with OI have issues with their balance and hearing. Researchers will assess the participants' hearing and balance, and if they find any problems, they might perform additional tests like a CT scan or MRI to get more information about their ears and inner ear structures.
To participate in the study, individuals must be between 12 and 20 years old and have a diagnosis of Osteogenesis Imperfecta. They should also be receiving care from a doctor at a specific medical center. However, certain conditions like specific types of hearing loss from other causes or serious neurological issues may prevent someone from joining the trial. If eligible, participants will undergo various hearing and balance tests, which are safe and non-invasive. This study aims to better understand the connection between OI and any related hearing or balance issues, which could help improve care for those with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between the ages of 12-20 years at the time of inclusion
- • Diagnosis of Osteogenesis Imperfecta of any type
- • Currently followed by a physician at the CRMR OI
- • Information and non-opposition of major patients, holders of parental authority and minor patients to participate in the study
- Exclusion Criteria:
- • Patients with hearing loss of alternate origin e.g. Cochlear nerve deficiency, atresia, etc.
- • Neurological or developmental deficits limiting participation
- • Cervico-occipital instability e.g. Chiari's malformation
- • Limitations in mobility of the spine e.g. scoliosis, spinal fractural fusion
- • Ophthalmologic pathologies e.g. strabism or severe refraction disorder
- • Patients under AME (State Medical Aid)
- • Protected adult patients, adults unable to express their consent, pregnant or breastfeeding women
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Natalie Loundon, MD, PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Marine Parodi, MD
Study Director
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials